Company / SG&A Expense
Bionano Genomics, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$35.1M
FY2025
5-year range
$35.1M / $92.8M
FY2021-FY2025
Trend
-32.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $93M to $35M over the past 2 years.
Based on SEC 10-K filings.
$35M in FY2025 with a 5-year CAGR of +2.5%.
Improved from $93M to $35M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -26.5%
- 5-Year CAGR
- +2.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +2.5%, indicating consistent growth.
- In FY2025, sg&a expense decreased 32.2% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.1M | -32.2% |
| FY2024 | $51.9M | -44.1% |
| FY2023 | $92.8M | +4.7% |
| FY2022 | $88.6M | +51.5% |
| FY2021 | $58.5M | +88.3% |
| FY2020 | $31.1M | +54.1% |
| FY2019 | $20.2M | +41.7% |
| FY2018 | $14.2M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026